Contribute Try STAT+ Today

Several prominent biotech and pharmaceutical executives are openly criticizing a huge price hike for a decades-old medicine and argue that the unexpectedly higher cost is due to the misuse of a federal law designed to encourage drug development for rare diseases. And the executives are using this to bolster a social compact they issued last month to address the debate over rising drug costs.

At issue is dehydrated alcohol, which hospitals and clinics have used for years to treat chronic pain or to prevent infections in patients who must receive nutrients intravenously. But after winning orphan designation and a seven-year monopoly to sell its injectable version for use with a specific heart procedure, Belcher Pharmaceutical began charging nearly $10,000 for a pack of 10 vials, up from $1,300.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This article erroneously describes the scope of exclusivity under the ODA. The ODA confers market exclusivity for a particular drug only for the rare disease indication. The exclusivity conferred to Belcher would not prevent other manufacturers from bringing dehydrated alcohol to market for other indications.

    The problem is that the cost to submit an NDA is high even if clinical trials are unnecessary – this is an unfortunate byproduct of FDA’s ill-considered Unapproved Drugs Initiative.

    For more, see here:

    • Hi Anna,

      Thanks for the note. Yes, you’re correct that the FDA unapproved drugs initiative is what prompted the agency to direct manufacturers of dehydrated alcohol to discontinue production, and that running new trials may be an undesirable undertaking.

      It’s also true that another company could win FDA approval to sell a version of dehydrated alcohol before the 2025 exclusivity awarded to Belcher expires. However, that could only occur if another company wins approval for a different, but also very specific indication and is granted orphan designation. In such a case, this would require studies which, as you note, come with a high cost. In any event, I’ve updated the story to clarify and reflect that point.

      Meanwhile, though, unless another company takes such a step, Belcher has its monopoly.

      All best,
      ed at pharmalot

    • Ed,

      Other companies could seek FDA approval for dehydrated alcohol for any indication other than the indication covered by Belcher’s orphan drug exclusivity. The other companies would not need to be granted orphan designation. The real culprit here is the Unapproved Drugs Initiative, which unnecessarily requires manufacturers to take their unapproved drugs off the market, even in cases such as this one where the product has an established record of safety and efficacy demonstrated by decades of use in medical practice.

    • Hi Anna,

      Thanks for the give and take.
      I’ve gone back to FDA to clarify and update previous conversations and yes, there are two issues here as noted. The combined one-two punch – the unapproved drug initiative and the orphan exclusivity – have created hurdles to competition and left Belcher with a wide open field to dominate, at least for now.
      Anyway, I appreciate you reaching out and the conversation.
      ed at pharmalot

Comments are closed.